Rifadin IV and Sofosbuvir Tablets

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using sofosbuvir together with rifAMPin is not recommended. Combining these medications may significantly reduce the blood levels of sofosbuvir, which may make the medication less effective in treating hepatitis C. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with rifampin may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral agents that may be given with sofosbuvir in fixed-dose combination products such as ledipasvir and velpatasvir. The proposed mechanism is induction of intestinal P-glycoprotein (P-gp)-mediated efflux by rifampin, which results in decreased oral bioavailability of the antiviral agents. Induction of CYP450 2B6, 2C8, and 3A4 may also contribute in the case of velpatasvir. In 17 healthy volunteers, administration of a single 400 mg dose of sofosbuvir during multiple dosing of rifampin 600 mg once daily reduced mean sofosbuvir peak plasma concentration (Cmax) and systemic exposure (AUC) by 77% and 72%, respectively. Likewise, administration of a single 90 mg dose of ledipasvir to 31 healthy volunteers during multiple dosing of rifampin 600 mg once daily decreased mean ledipasvir Cmax and AUC by 35% and 59%, respectively. When a single 100 mg dose of velpatasvir was given with rifampin 600 mg once daily to 12 healthy volunteers, velpatasvir Cmax decreased by 71% and AUC decreased by 82%.

MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of rifampin should generally be avoided during treatment with sofosbuvir, given either as a single-ingredient product or as a fixed-dose combination product with ledipasvir or velpatasvir.

Rifadin IV

Generic Name: rifampin

Brand name: Rifadin IV, Rifadin, Rimactane

Synonyms: n.a.

What is Rifadin IV?

Sofosbuvir Tablets

Generic Name: sofosbuvir

Brand name: Sovaldi

Synonyms: Sofosbuvir

What is Sofosbuvir Tablets?